Metastatic Renal Cell Carcinoma versus Pancreatic Neuroendocrine Tumor in von Hippel-Lindau Disease: Treatment with Interleukin-2

Metastatic Renal Cell Carcinoma versus Pancreatic Neuroendocrine Tumor in von Hippel-Lindau Disease: Treatment with Interleukin-2

Differentiating between clear cell neuroendocrine tumor (NET) of the pancreas and renal cell carcinoma (RCC) metastatic to the pancreas can be challenging in patients with von Hippel-Lindau disease (VHL). The clear cell features of both NET and RCC in VHL patients may lead to misdiagnosis, inaccurat...

Full description

Bibliographic Details
Main Authors: Christopher Williams, McClellan Walther
Format: Article
Language:English
Published: Hindawi Limited 2005-01-01
Series:The Scientific World Journal
Online Access:http://dx.doi.org/10.1100/tsw.2005.5
id doaj-41b64e1cbec04e8bb5d0abb5a0dd0586
record_format Article
spelling doaj-41b64e1cbec04e8bb5d0abb5a0dd05862020-11-24T20:56:09ZengHindawi LimitedThe Scientific World Journal1537-744X2005-01-01591010.1100/tsw.2005.5Metastatic Renal Cell Carcinoma versus Pancreatic Neuroendocrine Tumor in von Hippel-Lindau Disease: Treatment with Interleukin-2Christopher Williams0McClellan Walther1Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USAUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USADifferentiating between clear cell neuroendocrine tumor (NET) of the pancreas and renal cell carcinoma (RCC) metastatic to the pancreas can be challenging in patients with von Hippel-Lindau disease (VHL). The clear cell features of both NET and RCC in VHL patients may lead to misdiagnosis, inaccurate staging, and alternative treatment. We present a patient in which this occurred. As clear cell NETs closely resembling metastatic RCC are distinctive neoplasms of VHL and metastatic RCC to the pancreas in the VHL population is rare, careful pathologic examination should be performed prior to subjecting patients to definitive surgical or medical therapies.http://dx.doi.org/10.1100/tsw.2005.5
collection DOAJ
language English
format Article
sources DOAJ
author Christopher Williams
McClellan Walther
spellingShingle Christopher Williams
McClellan Walther
Metastatic Renal Cell Carcinoma versus Pancreatic Neuroendocrine Tumor in von Hippel-Lindau Disease: Treatment with Interleukin-2
The Scientific World Journal
author_facet Christopher Williams
McClellan Walther
author_sort Christopher Williams
title Metastatic Renal Cell Carcinoma versus Pancreatic Neuroendocrine Tumor in von Hippel-Lindau Disease: Treatment with Interleukin-2
title_short Metastatic Renal Cell Carcinoma versus Pancreatic Neuroendocrine Tumor in von Hippel-Lindau Disease: Treatment with Interleukin-2
title_full Metastatic Renal Cell Carcinoma versus Pancreatic Neuroendocrine Tumor in von Hippel-Lindau Disease: Treatment with Interleukin-2
title_fullStr Metastatic Renal Cell Carcinoma versus Pancreatic Neuroendocrine Tumor in von Hippel-Lindau Disease: Treatment with Interleukin-2
title_full_unstemmed Metastatic Renal Cell Carcinoma versus Pancreatic Neuroendocrine Tumor in von Hippel-Lindau Disease: Treatment with Interleukin-2
title_sort metastatic renal cell carcinoma versus pancreatic neuroendocrine tumor in von hippel-lindau disease: treatment with interleukin-2
publisher Hindawi Limited
series The Scientific World Journal
issn 1537-744X
publishDate 2005-01-01
description Differentiating between clear cell neuroendocrine tumor (NET) of the pancreas and renal cell carcinoma (RCC) metastatic to the pancreas can be challenging in patients with von Hippel-Lindau disease (VHL). The clear cell features of both NET and RCC in VHL patients may lead to misdiagnosis, inaccurate staging, and alternative treatment. We present a patient in which this occurred. As clear cell NETs closely resembling metastatic RCC are distinctive neoplasms of VHL and metastatic RCC to the pancreas in the VHL population is rare, careful pathologic examination should be performed prior to subjecting patients to definitive surgical or medical therapies.
url http://dx.doi.org/10.1100/tsw.2005.5
work_keys_str_mv AT christopherwilliams metastaticrenalcellcarcinomaversuspancreaticneuroendocrinetumorinvonhippellindaudiseasetreatmentwithinterleukin2
AT mcclellanwalther metastaticrenalcellcarcinomaversuspancreaticneuroendocrinetumorinvonhippellindaudiseasetreatmentwithinterleukin2
_version_ 1716790604235538432

Similar Items